HOME >> MEDICINE >> NEWS
Alcohol relapse adversely affects 10-year liver transplant survival

A new study on how alcohol relapse affects survival rates after liver transplants found that it adversely affected survival rates only after 10 years. The decrease in survival rates may, however, be due to other alcohol-related diseases.

The results of this study appear in the April 2005 issue of Liver Transplantation, the official journal of the American Association for the Study of Liver Diseases (AASLD) and the International Liver Transplantation Society (ILTS). The journal is published on behalf of the societies by John Wiley & Sons, Inc. and is available online via Wiley InterScience at http://www.interscience.wiley.com/journal/livertransplantation.

Alcoholic liver disease (ALD) is the second most common indication for liver transplants in the U.S. and Europe. Although reported survival rates after transplantation were similar between alcoholics and non-alcoholics (up to 60 percent at 7 years following transplant), concerns about alcohol relapse post-transplant have made the practice somewhat controversial, especially in light of the shortage of donor organs. To offset this risk, it is common practice to establish a 6 month period of abstinence from alcohol before listing a patient for liver transplant. Not only may improvement in liver function result, but higher rates of relapse have been reported in patients who have abstained for less than 6 months before undergoing transplantation. Although several previous studies analyzed the rate of alcohol relapse after liver transplantation and its influence on patient survival and transplant success, researchers had previously not studied patients for a longer follow-up period.

Led by Antonio Cuadrado, M.D. of the Gastroenterology and Hepatology Unit of the University Hospital "Marqus de Valdecilla" in Santander, Spain, the study expanded on a 1977 study involving 44 patients who underwent liver transplants for ALD an
'"/>

Contact: David Greenberg
dgreenbe@wiley.com
201-748-6484
John Wiley & Sons, Inc.
21-Mar-2005


Page: 1 2 3

Related medicine news :

1. Alcohol intervention attempted for violent males
2. Alcohols damaging effects on adolescent brain function
3. Alcohol drinkers three times as likely to die from injury
4. Alcohol: Global burden on health similar to tobacco and high blood pressure
5. Alcoholics can have deficits in visuoperception and frontal executive function despite sobriety
6. RFA safe for treating liver tumors pushing on GI tract; Alcohol injection makes RFA more effective
7. Alcohol consumption may be associated with irregular heart beat in men
8. Alcohol use and victimization among college women
9. Alcohol limit for drink driving should be much lower
10. Alcohol-related emergency department visits higher than previously thought
11. Alcohol abuse history could pose problems for HIV patients

Post Your Comments:
(Date:4/23/2014)... "simple and accessible detection methods that can rapidly ... of a single cell inside that population has ... Chang Lu. , In the Royal Society of ... announced that he and his coworkers have developed ... of a protein ( Chem. Sci. , 2014, ...
(Date:4/23/2014)... are often displayed in the popular Swedish children,s ... of high-sugar foods. A new study from the ... in children,s TV programmes as well as the ... and weight status. , Steingerdur Olafsdottir,s doctoral thesis ... popular Swedish children,s TV show Bolibompa. Healthy foods ...
(Date:4/23/2014)... led by a researcher from the Cancer Science Institute ... Singapore has identified the cancer specific stem cell which ... of developing new drugs for the treatment of this ... group, led by Dr Chan Shing Leng, Research Assistant ... that a cancer-specific variant of a cell surface protein, ...
(Date:4/23/2014)... in the journal Oncotarget , explored tumour ... or their own DNA signatures within the same ... design effective, targeted treatment strategies. , Firstly they ... and either the KRAS or BRAF mutation. Secondly, ... EGFR gene mutation have that specific mutation present ...
(Date:4/23/2014)... Alzheimer,s disease has been a rapidly evolving pursuit ... latest crook in the research road, scientists have ... proteins associated with the disease. The report, which ... , could have important implications for developing novel ... colleagues explain that for years, research has suggested ...
Breaking Medicine News(10 mins):Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:High-calorie and low-nutrient foods in kids' TV 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
(Date:1/14/2014)... InformEx, North America,s leading business partnering ... the 30 th edition of its annual conference at ... January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... and specialty chemical companies will take part in the conference, ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
Cached News: